戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 studied in the presence of a select group of cannabimimetics.
2                  These results indicate that cannabimimetics act presynaptically to inhibit the relea
3 ological assays for potential enhancement of cannabimimetic activities.
4 bind to the cannabinoid receptor and possess cannabimimetic activity yet are structurally dissimilar
5 sts in mouse behavioral assays indicative of cannabimimetic activity, including antinociception, hypo
6 e indole ring in compound 1 is essential for cannabimimetic activity.
7 n aliphatic hydroxyl (SAH) pharmacophore for cannabimimetic activity.
8 oups may be a characteristic requirement for cannabimimetic activity.
9 ize harmful side effects of cannabinoids and cannabimimetic agents.
10 aS to G-proteins and were shown to be potent cannabimimetic agonists.
11 onship) models (CoMFA models 1 and 2) of the cannabimimetic (aminoalkyl)indoles (AAIs) for CB1 cannab
12 ether (2-AGE), and anandamide (AEA)] and the cannabimimetic aminoalkylindole WIN 55,212-2 (WIN) inhib
13                                          The cannabimimetic aminoalkylindole WIN 55,212-2 inhibited w
14 mmodate a wide range of structurally diverse cannabimimetic analogues including the AAIs.
15             Several analogs of an endogenous cannabimimetic, arachidonylethanolamide (anandamide), we
16  and lipoxygenase and is mediated in part by cannabimimetic CB1 receptor, G protein, phosphoinositol
17                   Anandamide, the endogenous cannabimimetic compound, had an inconsistent effect on t
18 axant 2-arachidonoyl glycerol, an endogenous cannabimimetic derivative of arachidonic acid.
19                                 In contrast, cannabimimetics did not affect bicuculline-sensitive inh
20                                          The cannabimimetic drug Win55212-2 (100 nM) completely block
21                                          The cannabimimetic drug, Win 55212-2 (300 nM), inhibited FM1
22                                              Cannabimimetic drugs are of particular relevance to HAD
23                                              Cannabimimetic drugs did not protect cells from the dire
24                      These data suggest that cannabimimetic drugs may slow the progression of neurode
25                                              Cannabimimetic drugs prevented the recruitment of new sy
26 tiallodynic effects, possible tolerance, and cannabimimetic effects (e.g., hypothermia, catalepsy, CB
27 inistered in vivo, it induces only transient cannabimimetic effects as a result of its rapid cataboli
28 B2 receptors; however, unwanted CB1-mediated cannabimimetic effects limit clinical use.
29 B1 receptors with a significant reduction of cannabimimetic effects of CB1 agonists.
30 atory and neuropathic pain without producing cannabimimetic effects or physical dependence.
31  to reduce excitotoxicity, we tested several cannabimimetics in a model of synaptically mediated neur
32  and to search for more selective and potent cannabimimetic ligands.
33 t may participate in maintaining a supply of cannabimimetic N-acylethanolamines during synaptic activ
34 action of the southern aliphatic hydroxyl of cannabimimetic pharmacophores with the CB1 and CB2 recep
35 12-2, a synthetic cannabinoid that possesses cannabimimetic properties, acts as a novel regulator of
36 ding to cannabinoid receptors and of evoking cannabimimetic responses.
37 iallodynic efficacy, possible tolerance, and cannabimimetic side effects of repeated dosing with a CB
38 hic and inflammatory pain with minimal or no cannabimimetic side effects.
39 rawal efficacy, but is accompanied with some cannabimimetic side effects.
40 al body weight loss), but did not elicit any cannabimimetic side effects.
41 and the A current, were not modulated by the cannabimimetic WIN 55,212-2.
42                           Superfusion of the cannabimimetics WIN55212-2 or methanandamide onto CA1 ne

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。